Achilles Therapeutics PLC
NASDAQ:ACHL
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.12
1.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
A
|
Achilles Therapeutics PLC
NASDAQ:ACHL
|
60.8m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
386.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.2B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.5B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.6B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.7B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
48.4B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Achilles Therapeutics PLC
Glance View
Achilles Therapeutics Plc is a biopharmaceutical company engages in developing transformative precision T-cell therapies to treat multiple types of solid tumors. The firm has developed a bioinformatic platform called PELEUS, which is used to identify clonal neoantigens in patients. The firm's manufacturing process, VELOS, uses the patient’s T cells and blood-derived dendritic cells to create a clonal neoantigen targeting T cell therapy (cNeT). It's pipeline includes two single arm, open-label, proof-of-concept clinical trials in advanced non-small cell lung cancer (NSCLC) and metastatic or recurrent melanoma: CHIRON a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with advanced NSCLC, and THETIS a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with metastatic or recurrent melanoma.